How to accurately bring drugs to target cells and how to achieve high-efficiency payload has always been a problem encountered in scientific research. CD BioGlyco has developed a strategy that achieves site-specific antibody conjugation with Monomethyl auristatin E (MMAE) to solve this issue. Unlike traditional non-specific chemical conjugation, CD BioGlyco uses Site-Specific Antibody Conjugation, which can help you conjugate antibodies with MMAE, accurately bring MMAE to target cells, release them by high payload, and kill target cells in high-effective. We have the confidence to become your best scenic research assistant in the field of site-specific antibody-drug conjugate (ADC) study.
Due to the lack of site-specificity, traditional chemical conjugation strategies have led to product heterogeneity and irreproducibility of the reaction process, and potential modifications to the antigen recognition region might reduce the binding affinity and specificity of the antibody, moreover, modifications at multiple sites might lead to structural changes of the antibody, thus interfering with its potential biological function. Site-specific antibody conjugation strategy solves this problem. Site-specific conjugation produces a more homogeneous antibody conjugate that does not affect the biological activity of the conjugate. It also avoids modification of the antigen-binding region and has a higher binding efficiency than chemical conjugate. Site-specific antibody conjugation also improves plasma stability, reduces the variability of dose-dependent studies, and enhances binding affinity. Use site-specific antibody conjugation strategy to produce ADC, MMAE can be conjugated with site-specific antibodies to achieve targeted release of MMAE.
Fig.1 Binding and internalization of ADC followed by the release of its cytotoxins inside the cell. (Zhou, 2017)
MMAE is an antimitotic agent that kills cells by blocking the polymerization of microtubule proteins to inhibit cell division and thereby cause apoptosis. Because of the site-specific antibodies attached, the MMAE can be released accurately to the target cells to kill them, while the release of MMAE can be controlled and off-target toxicity reduced.
Fig.2 Chemical structure of MMAE. (Wikipedia)
CD BioGlyco's site-specific antibody conjugation is a technology based on Fc glycan remodeling and click chemistry. We produce site-specific ADC by uniquely conjugating MMAE to antibodies such as human IgG1-4, Fc-fusion proteins, and IgGs from animals (mouse, rabbit, rat, monkey, sheep, goat, cow, and horse).
Services we provide include but are not limited to:
Unlike traditional one-step reaction-activated ADCs, CD BioGlyco's site-specific antibody conjugation service has a cleavable glycopeptide linker, which is activated by lysosomes in a two-step reaction to control drug release in target cells, it can reduce drug instability and off-target effects. We also have outstanding scientists specializing in this service.
CD BioGlyco has advanced site-specific ADC production technology, and we have the confidence to meet customers' requirements about conjugating different antibodies with MMAE. If you are interested in our services, please contact us for more detailed information.
References:
